A Dose Titration of Droxidopa in Patients With Spinal Cord Injury

NCT ID: NCT01354158

Last Updated: 2013-07-30

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1
• Total Enrollment: 11 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2011-05-31
• Study Completion Date: 2013-05-31

Brief Summary

The investigators seek to determine the efficacy, duration of action and safety of escalating dose of droxidopa on systemic blood pressure, cerebral blood flow and vasoactive hormones and catecholamines during upright seated posture.

Primary Question:

1. What is the lowest dose of droxidopa that increases seated SBP to 115±5 mmHg in men and 105±5 mmHg in women?

• When does the defined increase in SBP occur after oral ingestion of droxidopa?
• How long does this dose of droxidopa sustain SBP at these levels?
• What are the vital signs and the subjective symptomology following droxidopa administration?

Secondary Question:

1. What is the MFV response to droxidopa administration in hypotensive individuals with SCI?

• Does an increase in SBP correspond to an increase in MCA MFV?

Tertiary Question:

1. What is the vasoactive hormone and catecholamine response to droxidopa administration in hypotensive individuals with SCI?

• Does droxidopa administration result in a change in APR, Aldo or NE in hypotensive individuals with SCI?

Detailed Description

Persons with spinal cord injury (SCI), due to partial to complete interruption of sympathetic pathways from the brainstem to the cardiovascular system are prone to blood pressure dysregulation including hypotension which is worsened during orthostasis. It is well established that orthostatic hypotension (OH) hinders the rehabilitation process during the acute phase of SCI but also may hamper the resumption of independence and activity in persons with chronic SCI. Surprisingly, only a few reports exist on the use and efficacy of an alpha receptor agonist (midodrine hydrochloride) to restore blood pressure to more normal levels in persons with tetraplegia. Our group has recently reported normalization of supine blood pressure with a relatively low dose of the nitric oxide synthase inhibitor (NOSi), nitro-L-arginine methyl ester (L-NAME). In addition to an alpha agonist and a NOSi, the use of a norepinephrine (NE) precursor, droxidopa, may be safe and efficacious for the treatment of orthostatic hypotension in a human model of SCI.

It has been demonstrated that the blood pressure-raising effect of 3,4-threo-dihydroxyphenylserine (droxidopa) occurs independently of the central nervous system in human models of neurologic OH by conversion to norepinephrine (NE) in neuronal and non-neuronal tissue. Oral droxidopa is taken up by the more peripheral sympathetic neurons, converted to NE, stored and released appropriately during postural stress. Droxidopa has been used for the effective treatment of OH in several human models of neurologically caused autonomic disorders, such as familial amyloid polyneuropathy, autoimmune autonomic neuropathy, pure autonomic failure, and multiple system atrophy . The effectiveness of droxidopa at improving orthostatic blood pressure in persons with SCI has not been studied. To date, only a single case on the use of the drug in a person with SCI has been reported and the use droxidopa in that case was successful. The purpose of this proposal is to determine the dose effectiveness, duration of action and any adverse events following droxidopa administration in hypotensive individuals with SCI.

To determine the efficacy, duration of action and safety of escalating dose of droxidopa on systemic blood pressure, cerebral blood flow and vasoactive hormones and catecholamines during upright seated posture.

Primary Question:

1. What is the lowest dose of droxidopa that increases seated SBP to 115±5 mmHg in men and 105±5 mmHg in women?

• When does the defined increase in SBP occur after oral ingestion of droxidopa?
• How long does this dose of droxidopa sustain SBP at these levels?
• What are the vital signs and the subjective symptomology following droxidopa administration?

Secondary Question:

1. What is the MFV response to droxidopa administration in hypotensive individuals with SCI?

• Does an increase in SBP correspond to an increase in MCA MFV?

Tertiary Question:

1. What is the vasoactive hormone and catecholamine response to droxidopa administration in hypotensive individuals with SCI?

• Does droxidopa administration result in a change in APR, Aldo or NE in hypotensive individuals with SCI?

Conditions

Spinal Cord Injury; Hypotension

Study Design

• Allocation Method: NON_RANDOMIZED
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Droxidopa

The dose-titration response to ascending doses of Droxidopa (placebo, 100mg, 200mg, 400mg) will be measured four separate days.

Group Type: EXPERIMENTAL

Droxidopa

Intervention Type: DRUG

Dose titration of placebo, 100mg, 200mg, 400mg of Droxidopa will be given to assess the effects of Droxidopa on blood pressure and cerebral blood flow.

Interventions

Droxidopa

Dose titration of placebo, 100mg, 200mg, 400mg of Droxidopa will be given to assess the effects of Droxidopa on blood pressure and cerebral blood flow.

Intervention Type: DRUG

Other Intervention Names

L-DOPs

Eligibility Criteria

Inclusion Criteria

• between the ages of 18 and 65,
• diagnosed with hypotension as defined above,
• able to provide informed consent

Exclusion Criteria

• Known or suspected sensitivity to study medication or any of its ingredients,
• current smoker,
• known coronary heart and/or artery disease,
• hypertension,
• diabetes mellitus or insipidus,
• thyroid disease,
• closed angle glaucoma,
• acute illness,
• major surgery in the last 30 days,
• renal diseases,
• pregnancy,
• recent history (within the past year) of cocaine use,
• tricyclic antidepressants, monoamine oxidase inhibitors, and catechol-O-methyltransferase inhibitors,
• currently taking vasoconstricting medicines, such as Midodrine, ephedrine, dihydroergotamine, and the triptan class of migraine drugs,
• Use of a halogen based anesthetic such as Halothane in the past 12 hours
• Currently taking Isoproterenol and other catecholamine preparations
• Peripheral Arterial Disease,
• Abdominal Aortic Aneurysm,
• Cerebrovascular Disease (Including prior CVA or TIA),
• History of or active Congestive Heart Failure,
• Known Systolic Dysfunction

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 65 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Chelsea Therapeutics

INDUSTRY

Sponsor Role: collaborator

Bronx VA Medical Center

FED

Sponsor Role: lead

Responsible Party

James J. Peters VA Medical Center

Principal Investigators

Jill M Wecht, EdD

Role: PRINCIPAL_INVESTIGATOR

James J. Peters VA Medical Center

Locations

James J. Peters VA Medical Center

The Bronx, New York, United States

Countries

United States

Other Identifiers

01272

Identifier Type: -

Identifier Source: org_study_id